KRAS Testing: A Tool for the Implementation of Personalized Medicine

摘要: Activating point mutations in codons 12, 13, and 61 of the KRAS proto-oncogene are common colorectal, non–small cell lung, pancreatic, thyroid cancers. Constitutively activated strongly associated with a resistance to anti–epidermal growth factor receptor (EGFR) therapies, such as panitumumab cetuximab used for treating metastatic colorectal carcinoma EGFR tyrosine inhibitors advanced lung Since anti-EGFR therapies costly may exert deleterious effects on individuals without activating mutations, mutation testing is recommended prior initiation therapy these malignancies. The goal this review summarize methods. Testing now routinely requested clinical practice provide data assign most appropriate anticancer chemotherapy each given patient. Review relevant literature was performed. Several areas were considered: ordering test, selection sample be tested, methodologies. We found that several different methods testing. Each methodologies described, information provided about their performance, cost, turnaround times, detection limits, sensitivities, specificities. also “tips” preparation tested. This an important aspect use, results test will affect decisions consequences